- Home
- IOVA
as 03-28-2025 4:00pm EST
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $20.25 | AVG Volume (30 days): | 9.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.33 - $14.77 | Next Earning Date: | 05-08-2025 |
| Revenue: | $164,070,000 | Revenue Growth: | 13698.99% |
| Revenue Growth (this year): | 180.51% | Revenue Growth (next year): | 59.81% |
Latest Iovance Biotherapeutics Inc. News
IOVA Breaking Stock News: Dive into IOVA Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket?
Motley Fool
7 days ago
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Motley Fool
7 days ago
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
GlobeNewswire
8 days ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
12 days ago
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts?
Motley Fool
17 days ago
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Simply Wall St.
25 days ago
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance
TipRanks
25 days ago
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan
Compare IOVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOVA Iovance Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.